US7781607B2 - Method for producing polymerized coordination compounds of platinum complex - Google Patents

Method for producing polymerized coordination compounds of platinum complex Download PDF

Info

Publication number
US7781607B2
US7781607B2 US11/921,784 US92178406A US7781607B2 US 7781607 B2 US7781607 B2 US 7781607B2 US 92178406 A US92178406 A US 92178406A US 7781607 B2 US7781607 B2 US 7781607B2
Authority
US
United States
Prior art keywords
platinum
cyclohexanediamine
group
nitrato
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US11/921,784
Other languages
English (en)
Other versions
US20080249256A1 (en
Inventor
Katsutoshi Kobayashi
Shoko Nagasaki
Kazunori Kataoka
Chieko Tsuchiya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NanoCarrier Co Ltd
University of Tokyo NUC
Original Assignee
NanoCarrier Co Ltd
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NanoCarrier Co Ltd, University of Tokyo NUC filed Critical NanoCarrier Co Ltd
Assigned to NANOCARRIER CO., LTD., UNIVERSITY OF TOKYO, THE reassignment NANOCARRIER CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KATAOKA, KAZUNORI, KOBAYASHI, KATSUTOSHI, NAGASAKI, SHOKO, TSUCHIYA, CHIEKO
Publication of US20080249256A1 publication Critical patent/US20080249256A1/en
Application granted granted Critical
Publication of US7781607B2 publication Critical patent/US7781607B2/en
Assigned to NANOCARRIER CO., LTD. reassignment NANOCARRIER CO., LTD. NOTICE OF CHANGE OF ASSIGNEE ADDRESS Assignors: NANOCARRIER CO., LTD.
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G85/00—General processes for preparing compounds provided for in this subclass
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/42—Polyamides containing atoms other than carbon, hydrogen, oxygen, and nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a method for producing a conjugate, in particular, a coordination compound, of a platinum complex useful as an anti-tumor agent and a block copolymer.
  • a certain kind of platinum complexes are useful as anti-tumor agent, and some of them have already been put to clinical use.
  • specific stereoisomers of dichloro(1,2-cyclohexanediamine)platinum(II) (hereinafter may be abbreviated as “Dach-Pt(chlorato)” in some cases) have been developed as analogs of cisplatin which has been clinically used of old as an anti-tumor agent, and great interest has been taken in them because of their anti-tumor activity superior to that of cisplatin.
  • Dach-Pt(chlorato) did not come to be clinically used mainly because of its low water-solubility.
  • conjugates of Dach-Pt with, for example, oxidized dextran or carboxymethoxydextran which are obtained by substituting the chlorato groups of Dach-Pt(chlorato) with a polymer having carboxyl groups on its side chains see Non-patent document 1; cited documents are collectively listed later
  • conjugate of poly(ethylene glycol)-block-poly(glutamic acid) and Dach-Pt see Non-patent document 2
  • Non-patent document 2 discloses that the conjugate described therein forms a polymer micelle and is solubilized in an aqueous medium, and shows not only anti-tumor activity comparable to oxaliplatin but also high drug stability and prolonged, high tumor accumulation.
  • the substitution of the chlorato groups of Dach-Pt(chlorato) with the polymer is carried out by treating the Dach-Pt(chlorato) with silver nitrate, removing the resulting silver chloride by filtration, converting the filtrate to corresponding diaquo-complex (occasionally abbreviated as Dach-Pt(hydroxo)) having improved water-solubility, by passing through anion-exchange resin, and reacting the complex with the polymer in water (see page 1088 of the document).
  • the silver chloride produced is removed by centrifugation (see the right column at page 226 of the document).
  • DLS dynamic light scattering
  • an objective of the present invention is to provide a substantially silver ion-free conjugate (or a coordination compound) of a block copolymer with a platinum complex, especially a conjugate of a block copolymer with Dach-Pt.
  • One method to achieve the objective is to thoroughly remove silver ion before a conjugate of a block copolymer and platinum complex is formed. As described in the Non-patent document 1, diaquo-platinum complex from which silver ion has been thoroughly removed may be used.
  • the present inventors found that the objective of the present invention could also be accomplished when the thorough silver ion elimination was carried out at the stage of bis(nitrato)-platinum complex which corresponds to a precursor of the diaquo-platinum complex and the resulting product was used as the starting material of the platinum complex.
  • a method for producing a coordination compound through reaction of platinum complex with a polymer having carboxyl groups on its side chains wherein a mixture of diaquo-platinum complex or bis(nitrato)platinum complex, in particular, the latter, with dihalo-platinum complex (dichloro-, diiodo, or dibromo-platinum complex) is used as the platinum complex; and a block copolymer represented by the following general formula (1) or (2):
  • R 1 represents hydrogen atom or an unsubstituted or substituted linear or branched C 1 -C 12 alkyl group
  • L 1 and L 2 each independently represents a linking group
  • R 2 represents methylene group or ethylene group
  • R 3 represents hydrogen atom, a protecting group of amino group, hydrophobic group or a polymerizable group
  • R 4 represents hydroxyl group, protected carboxyl group as formed together with the terminal —CO, or a hydrophobic group
  • R 5 s each independently represents a hydrogen atom, an alkali metal ion or a protecting group of carboxyl group
  • m represents an integer of 5 to 20,000
  • n represents an integer of 2 to 5,000
  • x represents an integer of 0 to 5,000, with the proviso that x is not larger than n
  • hydrogen atom or alkali metal ion occupies 50% or more, preferably 80% or more, and more preferably 100%, of n ⁇ x and x R 5 s, is used as the
  • diaquo(1,2-cyclohexanediamine)platinum(II) is used as the diaquo-platinum complex
  • bis(nitrato)(1,2-cyclohexanediamine)platinum(II) is used as the bis(nitrato)platinum complex
  • dichloro(1,2-cyclohexanediamine)platinum(II) is used as the dihalo-platinum complex.
  • a method for producing coordination compound through reaction of a platinum complex with a polymer having carboxyl groups on its side chains wherein as the starting material bis(nitrato)(1,2-cyclohexanediamine)platinum(II), diaquo(1,2-cyclohexanediamine)platinum(II) or a mixture of bis(nitrato)(1,2-cyclohexanediamine)platinum(II) and diaquo(1,2-cyclohexanediamine)platinum(II) is used, the platinum complexes being substantially free of silver ion, and a block copolymer represented by the general formula (1) or (2) above is used as the polymer, the method comprising a step of carrying out the reaction in an aqueous medium under the conditions that the platinum complex (including the mixture of platinum complexes) and the block copolymer mutually form a coordination compound and a step of recovering thus obtained coordination compound.
  • the ratio of platinum atoms in all of the platinum complex(es), preferably bis(nitrato)(1,2-cyclohexanediamine)platinum(II) (hereinafter may be abbreviated as Dach-Pt(nitrate)), to carboxylate groups in the block copolymer (on equivalent basis, which applies hereafter) is set to be more than 0.4, preferably 0.45 or more to 0.7 or less, more preferably 0.475 or more to 0.6 or less, and most preferably 0.5 or more to 0.55 or less.
  • Final concentration of total platinum complex(es) in the reaction liquid of the aqueous medium is set to be 2 mg/mL (approximately 4.6 mM) or less, preferably 1 mg/mL (approximately 2.3 mM) or less.
  • particle size distribution of the polymer micelles is an important factor for accumulating the drug in tumor through the enhanced permeability and retention (EPR) effect.
  • EPR enhanced permeability and retention
  • a solution containing polymer micelles which show a single peak on GPC measurement and furthermore a peak of narrow distribution of cumulant diameter which is one of the criteria for particle diameter, namely a narrow particle size distribution. Therefore, according to the present invention, there is provided an effective method for producing conjugates or coordination compounds that can be conveniently used as anti-tumor agents, for example those which can form polymer micelles suitable for providing stable and excellent EPR effect.
  • a coordination compound is a compound which is considered to contain coordination bond(s), wherein the coordinate bond exists between platinum of a platinum complex and a carboxyl group of a block copolymer.
  • conjugate of the block copolymer and platinum complex is used in the sense interchangeable with coordination compound.
  • Diaquoplatinum complex, bis(nitrato)-platinum complex or dihaloplatinum complex (dichloro-, diiodo-, or dibromo-platinum complex) which are useful platinum complexes may contain any other ligand(s) besides diaquo, bis(nitrato) or dihalo ligands so long as they meet with the objective of the present invention. Examples include the following, but not limited to these.
  • a diaquoplatinum complex may include diaquo(1,2-cyclohexanediamine)platinum(II), cis-diamine-diaquoplatinum (II), amino-diaquo-cyclohexylamine platinum (II), cis-amine-diaquo(2-methylpyridine)platinum (II) and the like, and diaquo(1,2-cyclohexanediamine)platinum(II) is particularly preferred.
  • a bis(nitrato)platinum complex may include bis(nitrato)(1,2-cyclohexanediamine)platinum(II), cis-diamine-dinitro platinum(II), amino-dinitro-cyclohexylamine platinum (II), cis-amine-dinitro(2-methylpyridine)-platinum(II) and the like, and bis(nitrato)(1,2-cyclohexanediamine)platinum(II) is particularly preferred.
  • dichloroplatinum complex can be preferably used, it may include dichloro(1,2-cyclohexanediamine)platinum complex, cis-diamine-dichloro-platinum(II), amino-dichloro-cyclohexylamine platinum(II), and cis-amine dichloro(2-methylpyridine)platinum(II) and the like, and dichloro(1,2-cyclohexanediamine)platinum(II) is particularly preferred.
  • “Substantially silver ion-free” means a condition that at the maximum not more than 20 ppm of silver is contained, and preferably silver cannot be detected by conventional methods (for example, atomic absorption method) or not contained at all.
  • Substantially silver ion-free diaquoplatinum complex or bis(nitrato)platinum complex, which are used as the starting material for the platinum complex can be obtained by treating the corresponding dichloroplatinum complex with silver nitrate, removing the produced silver chloride precipitate, and further removing the still remaining silver ion with, for example, reverse osmosis membrane, as described in JP Hei 5(1993)-301884A. Useful method for their preparation, however, is not limited thereto.
  • any block copolymer represented by the above general formula (1) or (2) can be used to achieve the objective of the present invention.
  • preferred block copolymers are those represented by the following general formula (1-a) or (2-a) or their salts:
  • R 1 , L 1 , L 2 , R 3 , R 4 and R 5 are the same as defined as to the general formulae (1) and (2), respectively; m represents an integer of 5 to 20,000; and n represents an integer of 10 to 60, provided that among n R 5 s, hydrogen atom or alkali metal ion occupies 50% or more, preferably 80% or more, more preferably 100%.
  • an unsubstituted or substituted, linear or branched C 1 -C 12 alkyl group includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, decyl and undecyl.
  • substituent includes an acetalized formyl group, cyano group, formyl group, carboxyl group, amino group, C 1 -C 6 alkoxycarbonyl group, C 2 -C 7 acylamido group, the same or different tri-C 1 -C 6 alkylsiloxy group, siloxy group, or silylamino group.
  • Poly(ethylene glycol) (PEG) segments having such a functional group at their one of the terminals can be conveniently produced according to those manufacturing methods for PEG segments of block polymers as described in, for example, WO96/32434, WO96/33233 and WO97/06202.
  • the block copolymers represented by the general formulae (1), (2), (1-a) or (2-a) thus produced can take any mode of linking depending on the manufacturing method used, and may be linked by any linking group so long as they meet the objective of the invention.
  • the methods include a method for producing object block copolymer by using a PEG derivative having a terminal amino group, polymerizing the same utilizing its amino terminal with, for example, N-carboxylic acid anhydride (NCA) of ⁇ -benzyl-L-aspartate and/or ⁇ -benzyl-L-glutamate, to synthesize a block copolymer, and then either converting the side chain benzyl groups to other ester groups or partially or completely hydrolyzing them.
  • NCA N-carboxylic acid anhydride
  • the structure of the copolymer becomes one represented by the general formula (1) or (1-a), and the linking group L 1 has a structure derived from the terminal structure of the PEG segment used, which preferably is —(CH 2 ) b —NH— (in which b is an integer of 1 to 5).
  • the copolymer according to the present invention can be produced by a method in which poly(carboxylic acid) or poly(amino acid or a derivative thereof) segment moiety is synthesized and then it is bound to a preliminarily prepared PEG segment moiety.
  • the copolymer produced may eventually have the same structure with that of the copolymer produced by the first described method, or a structure corresponding to the general formula (2) or (2-a).
  • the linking group L 2 is not particularly limited, preferably it is —(CH 2 ) c —CO— (in which c is an integer of 1 to 5).
  • R 5 can be each independently hydrogen atom or a protecting group of carboxyl group.
  • the protecting group of carboxyl group includes, but not limited thereto, benzyl, benzhydryl or C 1-6 alkyl group, specific examples of alkyl group being methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.
  • R 3 can be each independently hydrogen atom or a protecting group of amino group, for example, benzyloxycarbonyl, t-butyloxycarbonyl, acetyl or trifluoroacetyl group, and it can also be a hydrophobic group such as benzylcarbonyl or benzhydrylcarbonyl group and the like, or a polymerizable group such as acryloyl or methacryloyl group.
  • a protecting group of amino group for example, benzyloxycarbonyl, t-butyloxycarbonyl, acetyl or trifluoroacetyl group, and it can also be a hydrophobic group such as benzylcarbonyl or benzhydrylcarbonyl group and the like, or a polymerizable group such as acryloyl or methacryloyl group.
  • R 4 can be each independently hydroxyl group; protected carboxyl group with the terminal —CO, for example, benzyloxy carbonyl, t-butyloxycarbonyl or methoxycarbonyl group; a hydrophobic group such as benzyloxy or benzhydryloxy group; or a polymerizable hydrophobic group such as allyloxy or vinylphenylmethoxy group.
  • m is an integer of 5 to 20,000, preferably 10 to 5,000, more preferably 40 to 500
  • n is an integer of 2 to 5,000, preferably 5 to 1,000, more preferably 10 to 60, and most preferably 15 to 40. Therefore, although the moiety is expediently referred to as poly(ethylene glycol) or the like in the present specification, the prefix, “poly”, is used as a concept inclusive of also those which normally fall under the category of “oligo”.
  • x which determines the constitution ratio of two kinds of repeating units which can be present in the poly(amino acid or derivative thereof) segment, particularly poly(aspartic acid), can be an integer of 0 to 5,000 (but not larger than n).
  • each of the repeating units can be distributed randomly or in blocks.
  • the reaction conditions for forming the above described coordination compound comprising platinum complex and block copolymer include diaquoplatinum complex, in particular, Dach-Pt(hydroxo) or bis(nitrato)platinum complex, in particular, Dach-Pt(nitrato), to be present in an aqueous medium, in particular, water (which can be an aqueous solution containing a water-miscible organic solvent such as methanol, ethanol, acetonitrile, dimethylformamide or the like, where necessary), in an amount soluble in the aqueous medium at temperatures ranging 5° C.-90° C., although not limited thereto; then concurrent presence of the block copolymer; and gently stirring the mixture or allowing the mixture to stand, for a time sufficient for formation of the coordination compound. Although it is impossible to specify the sufficient time because it varies depending on the reaction temperature, it can be 10 to 96 hours at 37° C.
  • the use ratio of platinum atoms in the platinum complex to carboxylate groups in the block copolymer desirably is set to be more than 0.4, preferably 0.45 or more to 0.7 or less, more preferably 0.475 or more to 0.6 or less, most preferably 0.5 or more to 0.55 or less.
  • Coordination compounds obtained under such conditions form few or no aggregated polymer micelle in an aqueous medium and can form polymer micelles having virtually single peak as measured by GPC. Furthermore, the micelles can encapsulate about 80% or more of the platinum complex which is used in the reaction (charged amount).
  • Another preferred embodiment of the present invention is a method in which, as the starting materials of the platinum complex, a diaquoplatinum complex or a bis(nitrato)platinum complex, preferably Dach-Pt(hydroxo) or Dach-Pt(nitrato), especially Dach-Pt(nitrato), and a dihaloplatinum complex, preferably Dach-Pt(halogeno), especially dichloroplatinum complex, preferably Dach-Pt(chlorato) are caused to be present in an aqueous medium in mixed state and reacted with a block copolymer.
  • Example 10 of Japanese Patent Publication No. 2000-506855A (or WO97/33894), there is a disclosure stating that boiling of equimolar amounts of Dach-Pt(chlorato) and Dach-Pt(nitrato) in distilled water results in production of binuclear platinum complex (that is, a platinum complex having two platinum atoms in one molecule).
  • the coordination compound according to the present invention may also be produced via the binuclear complex in the presence of the block copolymer according to the present invention
  • the coordination compound produced in the present invention and forms the polymer micelles mainly carries a mono-nuclear platinum complex, when the factors including the nature of the reaction mixture are considered.
  • bis(nitrato)platinum complex preferably Dach-Pt(nitrato) and dihaloplatinum complex, especially dichloroplatinum complex, preferably Dach-Pt(halogeno), especially Dach-Pt(chlorato)
  • Such mixed or coexisting condition is preferably brought about by mixing bis(nitrato)platinum complex and dihaloplatinum complex in an aqueous medium, especially in water.
  • Source of such halide includes, although not limited thereto, hydrochloric acid, sodium chloride and potassium chloride for chloride ion; sodium iodide and potassium iodide for iodide ion; and potassium bromide, sodium bromide and hydrobromic acid for bromide ion.
  • the use ratio of the platinum complexes to block copolymer can be 4:10 to 4:1, preferably 4.5:10 to 2:1, more preferably 5:10 to 3:2, in terms of the ratio (equivalent ratio) of platinum atoms in the platinum complexes to carboxylate groups in the block copolymer.
  • Desired coordination compound is thus produced.
  • the coordination compound can be efficiently recovered or purified by using conventional methods for separating a polymer micelle, for example, dialysis or ultrafiltration or combination thereof because the compound automatically associates and forms stable polymer micelles encapsulating the platinum complexes in the reaction solution.
  • FIG. 1 is a GPC chart of the polymer micelle-containing solution as obtained in Example 1.
  • the abscissa axis represents the retention time (minutes) and the ordinate axis represents the output (mV) of ultraviolet absorptiometer.
  • FIG. 2 is a graph showing particle size distribution of the micelles in the polymer micelle-containing solution as obtained in Example 1, which was measured by dynamic light scattering method.
  • the abscissa axis represents the diameter (nm) and the ordinate axis represents relative intensity.
  • FIG. 3 is a GPC chart of the polymer micelle-containing solution as obtained in Example 2.
  • the abscissa axis and the ordinate axis have the same meanings as in FIG. 1 .
  • FIG. 4 is a graph showing particle size distribution of the micelles in the polymer micelle-containing solution as obtained in Example 2, which was measured by dynamic light scattering method.
  • the abscissa axis and the ordinate axis have the same meanings as in FIG. 2 .
  • FIG. 5 shows GPC charts of each of the reaction solutions prepared by using platinum atoms in the platinum complex and carboxylate groups in the block copolymer at the ratios as given in Example 3.
  • the abscissa axis and the ordinate axis have the same meanings as in FIG. 1 .
  • FIG. 6 is a graph showing the variation in the areas indicated in the GPC charts in FIG. 5 , the areas corresponding to the amounts of respectively formed polymer micelles.
  • the abscissa axis represents the use ratio of platinum atoms in the platinum complex to carboxylate groups in the block copolymer, and the ordinate axis represents the peak area [mV ⁇ sec.] of the micelles.
  • FIG. 7 shows GPC charts of the reaction solutions prepared by using two kinds of platinum complexes at the use ratios as given in Example 4.
  • the abscissa axis and the ordinate axis have the same meanings as in FIG. 1 .
  • FIG. 8 is a graph showing the variation in the areas indicated in the GPC charts in FIG. 7 , the areas corresponding to the amounts of respectively formed polymer micelles.
  • the abscissa axis represents ⁇ [cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) nitrate]/([cis-dichloro(trans-L-1,2-cyclohexanediamine)platinum(II)]+[cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II)] ⁇ , and the ordinate axis represents micelle's peak area [mV ⁇ sec].
  • FIG. 9 is a graph showing the variation in the area corresponding to the amount of polymer micelles in each of the reaction solutions obtained at varied use ratio of platinum atoms in the equimolar mixture of two kinds of platinum complexes to carboxylate in the block copolymer in Example 5.
  • the abscissa axis represents the use ratio of platinum atoms in the platinum complexes to carboxylate in the block copolymer, and the ordinate axis has the same meaning as in FIG. 8 .
  • FIG. 10 is a GPC chart of the reaction solution obtained in Example 6 when the two platinum complexes were formed in situ.
  • the abscissa axis and the ordinate axis have the same meanings as in FIG. 1 .
  • FIG. 11 shows GPC charts of the reaction solutions as obtained with varied concentration of cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) nitrate in the reaction solution, at varied ratio of platinum atom in cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) nitrate to the carboxylate in the block copolymer.
  • the abscissa axis and the ordinate axis have the same meanings as in FIG. 1 .
  • This Example describes a specific example in which Dach-Pt(nitrato) and Dach-Pt(chlorato) coexist as stating materials.
  • PEG-P(Glu) poly(ethylene glycol)-block-poly(glutamic acid)
  • PEG-P(Glu)12-20 poly(ethylene glycol)-block-poly(glutamic acid)
  • This Example describes a specific example in which Dach-Pt(nitrato) alone was used as the starting material and a coordination compound was formed at a specific ratio relative to carboxylate(Glu) in a block copolymer.
  • This example used Dach-Pt(nitrato) alone as the starting material and investigated the effect of the use ratio of platinum atoms in the platinum complex to the carboxylate (Glu) in the block copolymer on the configuration of the polymer micelles formed from the coordination compound.
  • the final concentration of cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) in each of the solutions was made 2 mg/mL (4.620 mmol/mL) and the solutions were allowed to react at 37° C. for 96 hours in a dark place. A portion of each of the resulting solutions was taken and subjected to GPC analysis under the same conditions as in Example 1. Thus obtained GPC charts are shown in FIG. 5 .
  • the correlation of the micellear area with [cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) nitrate]/[Glu] was as shown in FIG. 6 .
  • micellar area reached the maximum when [cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) nitrate]/[Glu] was 5.5/10. From FIG. 5 , it is inferred that those deemed to be aggregated polymer micelles were formed when the ratio of the platinum complex to the carboxylate was 7/10 to 6/10 because shoulder peaks were observed on the high molecular weight side.
  • This example investigates the effect of the mixing ratio of two kinds of platinum complexes on the configuration of the polymer micelles formed from the coordination compounds.
  • Cis-diaquo (trans-L-1,2-cyclohexanediamine)platinum(II) nitrate and cis-dichloro(trans-L-1,2-cyclohexanediamine)platinum(II) were dissolved in water at 70° C. at the molar ratios 9:1, 4:1, 2:1, 1:1, 1:2, 1:4 and 1:9, respectively (total 2.5 mmol/L).
  • micellar area The correlation of the micellar area with cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) nitrate:cis-dichloro(trans-L-1,2-cyclohexanediamine)platinum(II) was as shown in FIG. 8 .
  • the micellar area reached the maximum when cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) nitrate:cis-dichloro(trans-L-1,2-cyclohexanediamine)platinum(II) was 1:1.
  • This example investigates the effect of the use ratio of platinum atoms in the platinum complexes to the carboxylate (Glu) in the block copolymer on the configuration of the polymer micelles formed of the coordination compounds, when two kinds of platinum complexes are used.
  • Cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) nitrate and cis-dichloro(trans-L-1,2-cyclohexanediamine)platinum(II) were dissolved in water at 70° C. at a molar ratio of 1:1 (total 2.5 mmol/L).
  • micellar area The correlation of the micellar area with [cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) nitrate+cis-dichloro(trans-L-1,2-cyclohexanediamine)platinum(II)]/[Glu] is shown in FIG. 9 .
  • the micellar area reached the maximum at the [cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) nitrate+cis-dichloro(trans-L-1,2-cyclohexanediamine)platinum(II)]/[Glu] ratio of 1:1.
  • This example describes a specific example in which a coexisting state of two kinds of platinum complexes is brought about in situ.
  • This example used Dach-Pt(nitrato) alone as the starting material, to investigate the effect of its concentration in the reaction solution for forming the coordination compound, and investigated the effect of the use ratio of platinum atoms in the platinum complex to the carboxylate (Glu) in the block copolymer on the configuration of the polymer micelles formed of the coordination compounds.
  • Cis-diaquo(trans-L-1,2-cyclohexanediamine)platinum(II) nitrate was dissolved at concentration of 4.620 mmol/L, 2.309 mmol/L and 1.155 mmol/L at 70° C., and the solutions were cooled to about 37° C.
  • a portion of each of the reaction solutions was taken and subjected to GPC analysis under the same conditions as in Example 1.
  • the GPC charts obtained are shown in FIG. 11 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
US11/921,784 2005-06-09 2006-06-08 Method for producing polymerized coordination compounds of platinum complex Active 2026-07-02 US7781607B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005-169917 2005-06-09
JP2005169917 2005-06-09
PCT/JP2006/311969 WO2006132430A1 (fr) 2005-06-09 2006-06-08 Procede de fabrication d'un compose polymere coordonne d'un complexe de platine

Publications (2)

Publication Number Publication Date
US20080249256A1 US20080249256A1 (en) 2008-10-09
US7781607B2 true US7781607B2 (en) 2010-08-24

Family

ID=37498609

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/921,784 Active 2026-07-02 US7781607B2 (en) 2005-06-09 2006-06-08 Method for producing polymerized coordination compounds of platinum complex

Country Status (14)

Country Link
US (1) US7781607B2 (fr)
EP (3) EP1897900B1 (fr)
JP (1) JP5201572B2 (fr)
KR (1) KR101275968B1 (fr)
CN (1) CN101203549B (fr)
AU (1) AU2006255938B2 (fr)
CA (1) CA2611450C (fr)
DK (1) DK2656840T3 (fr)
ES (1) ES2555303T3 (fr)
HK (1) HK1120817A1 (fr)
PL (1) PL2656840T3 (fr)
PT (1) PT2656840E (fr)
RU (1) RU2382056C2 (fr)
WO (1) WO2006132430A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012174480A2 (fr) 2011-06-17 2012-12-20 Halozyme, Inc. Procédés de perfusion d'insuline sous-cutanée continue utilisant une enzyme de dégradation de l'hyaluronane
WO2013040501A1 (fr) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions et combinaisons d'accepteurs biologiques organophosphorés et d'enzymes dégradant le hyaluronane, et leurs utilisations
WO2015003167A1 (fr) 2013-07-03 2015-01-08 Halozyme, Inc. Variants de hyaluronidase ph20 thermiquement stables et leurs utilisations
EP3130347A1 (fr) 2011-12-30 2017-02-15 Halozyme, Inc. Variants polypeptidiques ph20, formulations et utilisations de ceux-ci

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232762A1 (en) * 2008-03-11 2009-09-17 May Pang Xiong Compositions for delivery of therapeutic agents
WO2010098265A1 (fr) * 2009-02-27 2010-09-02 国立大学法人 東京大学 Micelle polymère contenant un inhibiteur de protéasome
KR102005446B1 (ko) 2012-09-05 2019-07-31 삼성전자주식회사 과산화수소 민감성 금속 나노 입자, 그의 제조 방법 및 그를 포함하는 과산화수소 검출 시스템
EP3395857B1 (fr) * 2015-12-22 2021-05-26 Nippon Kayaku Kabushiki Kaisha Conjugué polymère à base d'un complexe de platine (ii) coordonné à un dérivé de sulfoxyde
CN118043077A (zh) * 2021-07-27 2024-05-14 嘉兴清准医药科技有限公司 载药单分子纳米聚合物、前药、胶束、药物递送系统及制备方法和用途
CN113929898B (zh) * 2021-10-09 2023-03-24 苏州大学 一种金属基纳米聚合物及其制备方法与应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115418A (en) * 1976-09-02 1978-09-19 Government Of The United States Of America 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity
US4200583A (en) * 1977-09-12 1980-04-29 Yoshinori Kidani New platinum complex
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
US4931553A (en) * 1988-05-11 1990-06-05 Gill Devinder S Platinum-polymer complexes and their use as antitumor agents
JPH0395196A (ja) 1989-09-08 1991-04-19 Nippon Kayaku Co Ltd 高純度白金錯体の製造方法
US5087616A (en) * 1986-08-07 1992-02-11 Battelle Memorial Institute Cytotoxic drug conjugates and their delivery to tumor cells
JPH0940685A (ja) 1995-07-25 1997-02-10 Tanaka Kikinzoku Kogyo Kk 白金錯体の合成方法
JPH09132583A (ja) 1995-11-10 1997-05-20 Tanaka Kikinzoku Kogyo Kk シス−オキザラート（トランス−（−）−１、２−シクロヘキサンジアミン）白金（ｉｉ）の製造方法
WO1997033894A1 (fr) * 1996-03-11 1997-09-18 Debiopharm Sa Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant
US5693751A (en) * 1989-05-11 1997-12-02 Research Development Corporation Of Japan Water soluble high molecular weight polymerized drug preparation
WO2002026241A1 (fr) 2000-09-26 2002-04-04 Center For Advanced Science And Technology Incubation, Ltd. Micelle polymere renfermant du cisplatine et utilisation
JP2003342168A (ja) 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
WO2004082718A1 (fr) 2003-03-20 2004-09-30 Nippon Kayaku Kabushiki Kaisha Preparation micellaire contenant un agent anticancereux faiblement soluble dans l'eau, et nouveau copolymere sequence

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05301884A (ja) 1992-04-22 1993-11-16 Tanaka Kikinzoku Kogyo Kk 白金錯化合物の製造方法
ATE226966T1 (de) 1995-04-14 2002-11-15 Kazunori Kataoka Polyethylenoxide mit einer saccharidgruppe an einem ende und einer anderen funktionellen gruppe am anderem ende sowie verfahren zu deren herstellung
RU2169742C2 (ru) 1995-04-19 2001-06-27 Катаока Казунори Гетеротелехелатный блок-сополимер и способ его получения
NZ313769A (en) 1995-08-10 2000-02-28 Kazunori Kataoka block polymer having a functional group presented on each end
EP1695991B1 (fr) * 2003-12-10 2010-02-17 TOUDAI TLO, Ltd. Complexe de coordination de diaminocyclohexaneplatine (ii) et d'un copolymere contenant un segment d'acide poly(carboxylique), et agent antitumoral comprenant ce complexe

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115418A (en) * 1976-09-02 1978-09-19 Government Of The United States Of America 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity
US4200583A (en) * 1977-09-12 1980-04-29 Yoshinori Kidani New platinum complex
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
US5087616A (en) * 1986-08-07 1992-02-11 Battelle Memorial Institute Cytotoxic drug conjugates and their delivery to tumor cells
US4931553A (en) * 1988-05-11 1990-06-05 Gill Devinder S Platinum-polymer complexes and their use as antitumor agents
US5693751A (en) * 1989-05-11 1997-12-02 Research Development Corporation Of Japan Water soluble high molecular weight polymerized drug preparation
JPH0395196A (ja) 1989-09-08 1991-04-19 Nippon Kayaku Co Ltd 高純度白金錯体の製造方法
JPH0940685A (ja) 1995-07-25 1997-02-10 Tanaka Kikinzoku Kogyo Kk 白金錯体の合成方法
JPH09132583A (ja) 1995-11-10 1997-05-20 Tanaka Kikinzoku Kogyo Kk シス−オキザラート（トランス−（−）−１、２−シクロヘキサンジアミン）白金（ｉｉ）の製造方法
WO1997033894A1 (fr) * 1996-03-11 1997-09-18 Debiopharm Sa Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant
WO2002026241A1 (fr) 2000-09-26 2002-04-04 Center For Advanced Science And Technology Incubation, Ltd. Micelle polymere renfermant du cisplatine et utilisation
US7125546B2 (en) * 2000-09-26 2006-10-24 Toudai Tlo, Ltd. Polymeric micelle containing cisplatin enclosed therein and use thereof
JP2003342168A (ja) 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
WO2004082718A1 (fr) 2003-03-20 2004-09-30 Nippon Kayaku Kabushiki Kaisha Preparation micellaire contenant un agent anticancereux faiblement soluble dans l'eau, et nouveau copolymere sequence

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Horacio Cabral et al., "Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II)(DACHPt)-loaded polymeric micelles", Journal of Controlled Release, vol. 101, pp. 223-232 (2005).
Nishiyama, Nobuhiro, et al.; Langmuir, 1999, 15 (2), p. 377-383. *
Y. Ohya et al. "Synthesis and cytotoxic activity of dextran carrying cis-dichloro(cyclohexane-trans-I-1,2-diamine)platinum(II) complex", Biomater. Sci. Polymer Edn., vol. 7, No. 12, pp. 1085-1096 (1996).

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012174480A2 (fr) 2011-06-17 2012-12-20 Halozyme, Inc. Procédés de perfusion d'insuline sous-cutanée continue utilisant une enzyme de dégradation de l'hyaluronane
WO2013040501A1 (fr) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions et combinaisons d'accepteurs biologiques organophosphorés et d'enzymes dégradant le hyaluronane, et leurs utilisations
EP3130347A1 (fr) 2011-12-30 2017-02-15 Halozyme, Inc. Variants polypeptidiques ph20, formulations et utilisations de ceux-ci
WO2015003167A1 (fr) 2013-07-03 2015-01-08 Halozyme, Inc. Variants de hyaluronidase ph20 thermiquement stables et leurs utilisations

Also Published As

Publication number Publication date
KR101275968B1 (ko) 2013-06-14
ES2555303T3 (es) 2015-12-30
KR20080020672A (ko) 2008-03-05
AU2006255938B2 (en) 2011-05-12
RU2382056C2 (ru) 2010-02-20
EP2474310B1 (fr) 2013-08-21
US20080249256A1 (en) 2008-10-09
EP2474310A1 (fr) 2012-07-11
PL2656840T3 (pl) 2016-03-31
JPWO2006132430A1 (ja) 2009-01-08
CN101203549B (zh) 2011-04-13
CA2611450C (fr) 2013-12-24
HK1120817A1 (en) 2009-04-09
EP1897900B1 (fr) 2013-08-07
AU2006255938A1 (en) 2006-12-14
WO2006132430A1 (fr) 2006-12-14
DK2656840T3 (en) 2015-11-02
EP1897900A1 (fr) 2008-03-12
CA2611450A1 (fr) 2006-12-14
RU2007148462A (ru) 2009-06-27
PT2656840E (pt) 2016-01-20
EP2656840A1 (fr) 2013-10-30
EP1897900A4 (fr) 2011-09-28
JP5201572B2 (ja) 2013-06-05
CN101203549A (zh) 2008-06-18
EP2656840B1 (fr) 2015-09-16

Similar Documents

Publication Publication Date Title
US7781607B2 (en) Method for producing polymerized coordination compounds of platinum complex
AU2004297126B2 (en) Coordination complex of diaminocyclohexaneplatinum(II) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same
Montague et al. Synthesis of poly [bis (trifluoroethoxy) phosphazene] under mild conditions using a fluoride initiator
EP1867673B1 (fr) Compose de coordination compose du diaminocyclohexane platine (ii) et d'un copolymere sequence et agent anticancereux le comprenant
US7598318B2 (en) Thermosensitive and biocompatible amphiphilic poly(organophosphazenes) and preparation method thereof
Haxton et al. Hyperbranched polymers for controlled release of cisplatin
Song et al. Synthesis, characterization, and tumor selectivity of a polyphosphazene–platinum (II) conjugate
EP1618117A1 (fr) Agent antitumoral selectif vis-a-vis des tumeurs et biodegradable de conjugue de polyphosphazene-platine (ii), et son procede de preparation
Neuse et al. cis-Diaminedichloroplatinum (II) complexes reversibly linked into the main chain of water-soluble polyamides
US11179475B2 (en) Biodegradable functional polycarbonate nanoparticle carries for delivering molecular cargo

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF TOKYO, THE, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOBAYASHI, KATSUTOSHI;NAGASAKI, SHOKO;KATAOKA, KAZUNORI;AND OTHERS;REEL/FRAME:020389/0776

Effective date: 20071226

Owner name: NANOCARRIER CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOBAYASHI, KATSUTOSHI;NAGASAKI, SHOKO;KATAOKA, KAZUNORI;AND OTHERS;REEL/FRAME:020389/0776

Effective date: 20071226

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: NANOCARRIER CO., LTD., JAPAN

Free format text: NOTICE OF CHANGE OF ASSIGNEE ADDRESS;ASSIGNOR:NANOCARRIER CO., LTD.;REEL/FRAME:033356/0500

Effective date: 20140616

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552)

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12